Vegetarian In Boston
Maynard S. Clark's Veggie and Boston Blog talks about vegetarian topics AND Boston-related topics, often intersecting them interestingly.
Maynard S. Clark is a long-time and well-known vegan in Greater Boston, who often quips in his 'elevator pitch':
"I've been vegan now for over half my natural life, longer than most human earthlings have been alive."
You are receiving Our Planet, our FREE newsletter, because you provided your e-mail to us at an event, on emagazine.com, or through the mail. If you do not wish to receive Our Planet, please use the link above to un-subscribe.
NEWS THIS WEEK
Brighter Idea Than the CFL May Soon Hit the Market Reported by Jessica Rae Patton Compact fluorescent light bulbs (CFLs), though far more energy efficient than their incandescent forbears, leave a lot to be desired. Go to all articles - Go to this article
Grizzlies Make the List Reported by Jessica Rae Patton According to the Greater Yellowstone Coalition, "In the past two years grizzly mortality has risen alarmingly...[and] their future remains precarious." Go to all articles - Go to this article
Reporting by Jessica Rae Patton
THIS WEEK'S COMMENTARY
Igniting Activists It's the 40th Anniversary of Earth Day-Are You Ready to Get to Work? Last year, Earth Day took some heat by online green scorekeepers, but this year-the celebration's 40th-it's reasserting its prominence. By Brita Belli Go to all articles - Go to this article
IN THE CURRENT ISSUE OF E
GREEN LIVING
Lessons from Etsy Tips for Taking Your Eco-Ideas Online Get crafty with home-biz tips from these eco-entrepreneurs. By Jessica A. Knoblauch Go to all articles - Go to this article
CURRENTS
Surviving the Downturn Environmental Nonprofits Face a New Economic Reality Environmental nonprofits are riding out the recession by joining forces-and office space. By Kristin Bender Go to all articles - Go to this article
EARTHTALK
Week of 9/27/09 Dear EarthTalk: As I understand it, hair salons are pretty toxic enterprises on many counts. Are there any efforts underway to green up that industry?
Dear EarthTalk: Not long ago there were concerns about honey bees disappearing. Are the bees still disappearing, and if so do we know why and do we have a solution? Go to this week's EarthTalk
WE NEED YOUR SUPPORT
This content is brought to you as a free public service by E/The Environmental Magazine, which is published by Earth Action Network, Inc., a non-profit 501 (c) (3) organization. Our address is 28 Knight Street, Norwalk, CT 06851.
Today at lunchtime I attended an HSPH presentation on www.mocamobile.org (MIT and HSPH developers for global health applications by cellphone/wireless devices that transmit photos and patient info to secure servers) and www.dossia.org (employer-insured systems that collaborated with MIT and HSPH developers - builds in patient incentives to personal responsibility for maintaining and developing personal wellness).
Dr. Leon Eisenberg, who conducted some of the first rigorous studies of autism, attention deficit disorder and learning delays and became a prominent advocate for children struggling with disabilities, died on Sept. 15 at his home in Cambridge, Mass. He was 87.
Dr. Leon Eisenberg
The cause was prostate cancer, said his wife, Dr. Carola Eisenberg.
The field of child psychiatry was dominated by Freudian psychoanalysis when, in the late 1950s and 1960s, Dr. Eisenberg began conducting medical studies of children with developmental problems. Working at Johns Hopkins University with Dr. Leo Kanner, who first described autistic behavior, Dr. Eisenberg completed the first detailed, long-term study of children with autism, demonstrating among other things that language problems predicted its severity.
In a similar study among children who were developing normally, Dr. Eisenberg showed that reading difficulties early in school predicted behavior problems later on.
In the 1960s, he performed the first scientific drug trials in child psychiatry, testing stimulants like Dexedrine and Ritalin to soothe the behavior of children identified as “delinquent” or “hyperkinetic.” These studies, which became the basis for drug treatment of what is now called attention deficit disorder, ran counter to psychoanalytic theories on the most effective treatments.
“Leon took a very courageous stand and denounced the way psychiatry treated children, this whole system in which we had a few rich kids and their parents getting psychoanalysis five days a week and still not being cured,” said C. Keith Conners, a professor emeritus in the department of psychiatry and behavioral sciences at Duke University. “No one even knew what a cure looked like. He had this conviction that nothing was being done for the bulk of children who needed help, and that we had very little scientific data to guide us.”
Dr. James Harris, a professor of psychiatry and behavioral science at Johns Hopkins University, said that Dr. Eisenberg was “the pivotal person in 20th-century child psychiatry who moved the field from simple descriptions of childhood disorders to actually looking at the science behind both the diagnosis and treatment.”
Leon Eisenberg was born in Philadelphia on Aug. 8, 1922, the eldest child of immigrants from Russia. He earned his undergraduate degree and, in 1946, his medical degree from the University of Pennsylvania, before taking an internship at Mount Sinai Hospital in New York, where he developed an interest in psychiatry. He completed his psychiatric residency at Sheppard Pratt Hospital in Towson, Md.
After two years in the Army teaching physiology (Carey incorrectly said psychology), in 1952 he began a residency at Johns Hopkins and his collaboration with Dr. Kanner. In 1967, he took over as chief of psychiatry at Massachusetts General Hospital, where he continued to publish and, among many other projects, helped formulate and carry out affirmative action policies at Harvard Medical School.
In 1980, he established the medical school’s department of social medicine, with the aim of applying the tools of social science to improving access to and practice of medicine worldwide.
In addition to his wife, a co-founder of Physicians for Human Rights, Dr. Eisenberg is survived by two children from a previous marriage, Kathy and Mark Eisenberg; two stepchildren, Alan and Larry Guttmacher; two sisters, Essie Ellis and Libby Wickler; and six grandchildren.
For two days last week, Harvard lowered its flags to half-staff in honor of Dr. Eisenberg.
In his later years, Dr. Eisenberg became increasingly alarmed at trends in the field he helped establish, criticizing what he saw as a cozy relationships between drug makers and doctors and the expanding popularity of the attention deficit diagnosis.
The diagnosis “has morphed from a relative uncommon condition 40 years ago to one whose current prevalence is 8 percent,” he wrote. “Correspondingly, the prescription of stimulant drugs has gone up enormously. The reasons are not self-evident.”
The New York Times heralded "A Win for Injured Patients,"1 whilethe Wall Street Journal said that the U.S. Supreme Court was"Pre-empting Drug Innovation."2 To the New York Times, the Court'sdecision in Wyeth v. Levine was "wise and surprising."1 To theWall Street Journal, it was a "defeat for drug innovation andpublic health"2; the editorial expressed surprise because theSupreme Court had earlier ruled that Congress had preemptedstate civil lawsuits alleging device misbranding, and many personsthought that the Court had turned relentlessly pro-businessand would therefore also rule that civil lawsuits alleging drugmisbranding . . . [Full Text of this Article] The Facts in Wyeth The Law of Preemption "Tragic Facts" Preemption after Wyeth
Source Information From the Department of Health Law, Bioethics, and Human Rights, Boston University School of Public Health, Boston. References
A win for injured patients. New York Times. March 5, 2009.
Pre-empting drug innovation. Wall Street Journal. March 5, 2009:A16.
Rosen J. Supreme Court, Inc. New York Times Magazine. March 16, 2008.
Wyeth v. Levine, 129 U.S. 1187 (2009).
Curfman GD, Morrissey S, Drazen JM. Why doctors should worry about preemption. N Engl J Med 2008;359:1-3. [Free Full Text]
Northern Securities v. United States, 193 U.S. 197, 400 (1904).
Glantz LH, Annas GJ. The FDA, preemption, and the Supreme Court. N Engl J Med 2008;358:1883-1885. [Free Full Text]
Kennedy D. Misbegotten preemptions. Science 2008;320:585-585. [Free Full Text]
Committee on the Assessment of the US Drug-Safety System. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2007.
Psaty BM, Burke SP. Protecting the health of the public -- Institute of Medicine recommendations on drug safety. N Engl J Med 2006;355:1753-1755. [Free Full Text]
Gilhooley M. Drug preemption and the need to reform the FDA consultation process. Am J Law Med 2008;34:539-561. [Web of Science][Medline]
Wyeth v. Levine, 944 A.2d 179 (Vt. 2006).
Riegel v. Medtronic, 128 U.S. 999 (2008).
71 C.F.R. 3922 (2006).
Geier v. American Honda Motor Co., 529 U.S. 861 (2000).
Curfman GD, Morrissey S, Drazen JM. The Medical Device Safety Act of 2009. N Engl J Med 2009;360:1550-1551. [Free Full Text]